ArticleFrontiers in immunology2020
A Pauci-Immune Synovial Pathotype Predicts Inadequate Response to TNFα-Blockade in Rheumatoid Arthritis Patients.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
9.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Evaluation of the Synovial Effects of Biological and Targeted Synthetic DMARDs in Patients with Psoriatic Arthritis: A Systematic Literature Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Trial
- Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.Nature medicine · 2022Trial
- Fibroblast-like synoviocytes exacerbate autoimmune arthritis upon psychological stress in an IL-6-dependent manner.Science advances · 2026Article
- Targeted Sequencing-Based Re-Evaluation of Candidate Immunogenetic Variants for Biologic Treatment Response and Difficult-to-Treat Rheumatoid Arthritis.International journal of molecular sciences · 2026Article
- When inflammation is not the driver: Pauci-immune synovitis and the stromal basis of refractory arthritis.EULAR rheumatology open · 2026Review
- Article
- Targeting fibroblasts in immune mediated inflammatory diseases: a cellular basis for cure?Rheumatology (Oxford, England) · 2026Review
- P2X7R of synovial fibroblasts is a potential therapeutic target associated with refractory rheumatoid arthritis.Science advances · 2026Article
- Scalable synovial fibroblast sources enable reproducible basal synovial organoid formation: an in vitro platform study.Rheumatology international · 2026Article
- Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Revisiting osteoarthritis as an inflammatory disease: characterization of synovitis grading and synovial pathotypes in surgical specimens.Arthritis research & therapy · 2026Article
- Spatial patterning of fibroblast TGFβ signaling underlies treatment resistance in rheumatoid arthritis.Nature immunology · 2026Article
- Pathogenic Drivers of Difficult-to-Treat Rheumatoid Arthritis: Synovium and Beyond.International journal of molecular sciences · 2026Review
- The value of contrast-enhanced ultrasound in synovial pathotypes of rheumatoid arthritis: an exploratory study.European radiology · 2026Article
- Biomarkers in Rheumatoid Arthritis: From Traditional Serology to Precision Medicine Integration.Diagnostics (Basel, Switzerland) · 2026Review
- Spatial transcriptomics reveals immune-stromal crosstalk within the synovium of patients with juvenile idiopathic arthritis.JCI insight · 2026Article
- Failed resolution as a mechanistic basis of difficult-to-treat rheumatoid arthritis: stromal-myeloid crosstalk in the synovium and emerging resolution-restoring therapies.Frontiers in immunology · 2026Review
- Biomarkers of treatment response in rheumatoid arthritis: from conventional markers to tissue immunophenotype.Frontiers in immunology · 2026Review
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Alessandra NervianiExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Maria Di CiccoExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Arti MahtoExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Gloria Lliso-RiberaExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Felice RivelleseExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Georgina ThorbornExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Rebecca HandsExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Mattia BellanExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Daniele MauroExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Marie-Astrid BoutetExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Giovanni GiorliExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Myles LewisExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Stephen KellyExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Michele BombardieriExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Frances HumbyExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Costantino PitzalisExperimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Queen Mary University of London · GBWilliam Harvey Research Institute · GB
Funding
Arthritis Research UK 20022Department of Health TRF-2018-11-ST2-002Medical Research Council G0800648Medical Research Council MR/K020250/1Versus Arthritis 21890Versus Arthritis 22000
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAntirheumatic AgentsArthritis, RheumatoidBiological TherapyCertolizumab PegolEndoscopic Ultrasound-Guided Fine Needle AspirationFemaleFollow-Up StudiesHumansImmunohistochemistryMacrophagesMaleMiddle AgedPlasma CellsPrognosisSynovial MembraneAntirheumatic AgentsCertolizumab PegolTNF protein, humanTumor Necrosis Factor-alphaanti-TNFcertolizumab-pegolpathotyperheumatoid arthritissynovial tissue
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.